Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2021
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics and Transaction Details
- Principal Amount: $63,750
- Net Proceeds: $60,000 (intended for general working capital)
- Transaction Costs: $3,750 paid to the investor for fees and expenses
- Interest Rate: 8% per annum (payable in cash or shares upon maturity/acceleration)
- Maturity Date: September 22, 2022
- Investor: Geneva Roth Remark Holdings, Inc.
Material Changes and Terms
The filing details the execution of a Securities Purchase Agreement and an 8% Convertible Promissory Note. Key terms include:
- Conversion Rights: Geneva may convert principal to common stock starting March 21, 2022. The conversion price is set at 65% of the "Market Price" (a 35% discount), defined as the average of the lowest three trading prices over the ten trading days prior to conversion.
- Prepayment Penalties: The note includes escalating prepayment premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Provisions: Upon certain events of default, the outstanding obligation accelerates to 150% of the principal plus accrued interest. A penalty of $1,000 per day applies if shares are not delivered within three business days of a conversion notice.
- Covenants: The Company is restricted from disposing of assets that would render it a "shell company" without consent and must maintain listing on an OTC market or equivalent exchange.
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use the net proceeds for general working capital purposes. The transaction is expected to close on or about September 29, 2021.
Risks and Contingencies:
- Dilution Risk: Conversion is subject to a 35% discount to market price, which may significantly dilute existing shareholders if the stock price rises.
- Default Risk: The 150% default penalty and daily late delivery fees create substantial financial liability in the event of operational or administrative failures.
- Liquidity Constraints: Prepayment is heavily penalized for the first six months, limiting the Company's ability to refinance or repay the debt early without significant cost.
- Reporting Requirements: Failure to comply with SEC reporting requirements or maintain an OTC listing constitutes an event of default.
Investor Verification Checklist
- Verify the closing date of the transaction (expected September 29, 2021) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Note (Exhibit 4.1) for additional covenants not summarized here.
- Monitor the Company's ability to maintain its OTC listing status to avoid triggering a default event.
- Assess the impact of the 35% conversion discount on potential future dilution of common stock.
- Confirm the Company's current cash position to ensure it can meet the 8% interest obligation or share issuance requirements upon maturity.